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GPCR oligomerizationWhile the G protein-coupled receptor (GPCR) oligomerization has been questioned during the last ﬁfteen years,
the existence of a multi-receptor complex involving direct receptor–receptor interactions, called receptor
oligomers, begins to be widely accepted. Eventually, it has been postulated that oligomers constitute a distinct
functional form of the GPCRs with essential receptorial features. Also, it has been proven, under certain
circumstances, that the GPCR oligomerization phenomenon is crucial for the receptor biosynthesis, maturation,
trafﬁcking, plasma membrane diffusion, and pharmacology and signalling. Adenosine receptors are GPCRs that
mediate the physiological functions of adenosine and indeed these receptors do also oligomerize. Accordingly,
adenosine receptor oligomers may improve the molecular mechanism by which extracellular adenosine signals
are transferred to the G proteins in the process of receptor transduction. Importantly, these adenosine receptor-
containing oligomers may allow not only the control of the adenosinergic function but also the ﬁne-tuning
modulation of other neurotransmitter systems (i.e. dopaminergic and glutamatergic transmission). Overall, we
underscore here recent signiﬁcant developments based on adenosine receptor oligomerization that are essential
for acquiring a better understanding of neurotransmission in the central nervous system under normal and
pathological conditions. This article is part of a Special Issue entitled: “Adenosine Receptors”.osine Receptors”.
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Adenosine is an endogenous nucleoside mostly formed as a
degradation product of adenosine triphosphate (ATP) and to a lesser
degree from S-adenosyl-L-homocysteine (SAH) metabolism. As soon
1246 F. Ciruela et al. / Biochimica et Biophysica Acta 1808 (2011) 1245–1255as adenosine has been generated it can be either intracellularly
phosphorylated to form AMP or eliminated out of the cells by means
of ubiquitous nitrobenzylthioinosine-sensitive equilibrative nucleo-
side transporters (ENTs). Additionally, adenosine can react with L-
homocysteine to form SAH. Finally, both intra- and extracellular
adenosine can be deaminated to form inosine by the action of intra-
and ecto-adenosine deaminase, respectively. Interestingly, as an
intermediate metabolite in several biochemical pathways, adenosine
plays a key regulatory role in numerous physiologic processes,
including platelet function, coronary and systemic vascular tone,
and lipolysis in adipocytes. In the nervous system, since the
extracellular concentration of adenosine raises as a function of the
neuronal activity, it acts as an energy dependent neuromodulator
through combined presynaptic, postsynaptic and non-synaptic
actions [1,2]. Therefore, extracellular adenosine regulates several
functions in the brain, including neuronal viability, neuronal mem-
brane potential, propagation of action potentials, astrocytic functions,
microglia reactivity, primary metabolism in both neurons and
astrocytes, and blood ﬂow [2]. Consequently, the physiological roles
and potential therapeutic use of adenosine have been extensively
revised over the last years [3,4].
Adenosine mediates its actions through the activation of speciﬁc
GPCRs, for which four subtypes have been identiﬁed (A1R, A2AR, A2BR
and A3R) [5]. These receptors have a distinctive pharmacological
proﬁle, tissue distribution and effector coupling [6], and its function-
ing has been extensively studied in the central nervous system (CNS)
(Table 1). Interestingly, A1Rs and A2ARs are largely responsible for the
central effects of adenosine [7]. The most abundant and homoge-
neously distributed adenosine receptor in the brain is the inhibitory
A1R, which is functionally coupled to members of the pertussis toxin-
sensitive family of G proteins (Gi/o) and whose activation regulates
the activity of membrane and intracellular proteins such as adenylate
cyclase, Ca2+ channels, K+ channels and phospholipase C (Table 1)
[8]. In contrast, the A2AR is expressed at high levels in only a few
regions of the brain, namely the striatum, the olfactory tubercle and
the nucleus accumbens [9]. The A2AR is mostly coupled to Gs in the
peripheral systems but mediates its effects predominantly through
activation of Golf in the striatum [10], thus activating adenylyl cyclase
which in turn converts ATP into cAMP (Table 1). Next, the A2BR is
positively coupled to adenylyl cyclase and PLC through a Gs and Gq
protein, respectively [11] (Table 1). The A2BR is thought to be fairly
ubiquitous in the brain, but the association of the A2BR to speciﬁcTable 1
Adenosine receptors.
Receptor Adenosine afﬁnity (EC50)a G protein
A1R ~50 nM Gi1,2,3c
Go
A2AR ~1 μM GS c
Golf
G15,16 d
A2BR N10 μM GS c
Gq/11 d
A3R ~50 nM Gi2,3c
a Data are from a cyclic AMP functional assay in CHO cells expressing the corresponding ad
inhibitor nitrobenzylthioinosine (NBTI) to avoid adenosine uptake.
b AC, adenylyl cyclase; PLC, phospholipase C; IP3, inositol triphosphate; DAG, diacylglycer
inwardly rectifying K+ channels; AA, arachidonic acid.
c Main mechanism of coupling.
d Receptor transfected cell system.physiological or behavioral responses remains quite difﬁcult because
of the lack of good A2BR selective agonists or antagonists [12].
Ultimately, the A3R has also been found to inhibit adenylyl cyclase,
and to promote calciummobilization probably by direct G protein βγ-
subunits PLC activation (for review see [3]) (Table 1). Interestingly, in
humans the A3R is a high afﬁnity receptor antagonized by xanthines
[13,14]. Finally, it is important tomention here that different classes of
proteins, other than G proteins, have been shown to interact with
adenosine receptors and to eventually modify their functioning [15].
2. Adenosine receptor containing oligomers
The concept of GPCRs oligomerization was ﬁrst postulated in the
1980s by Luigi F. Agnati and Kjell Fuxe, who proposed that an
intramembrane neuropeptide and monoamine receptor–receptor
interaction was responsible for the functional cross-talk observed
between these two neurotransmitter systems [16,17]. The initial
indirect evidence pointing to the existence of GPCR oligomers
containing neuropeptide and monoamine receptors was established
by means of radioligand-binding experiments. Thus, by using this
approach the existence of interactions between neurokinin NK1 and
5-HT1 receptors, CCK-2 and serotonin 5-HT2 receptors, vasoactive
intestinal peptide (VIP) and serotonin 5-HT1 receptors, cholecystoki-
nin CCK-2 and dopamine D2 receptors, neurotensin NTS1 and
dopamine D2 receptors, and neuropeptide Y (NPY) and α2 adrenergic
receptors were established (for review see [18]). In addition, some
photo-afﬁnity labelling and radiation inactivation experiments,
together with hydrodynamic and cross-linking analysis, also sup-
ported the GPCR oligomerization idea [19–22]. Later on, as the
existence of some GPCR homodimers in native tissue was demon-
strated (i.e. the dopamine D2 and the adenosine A1 receptor
homodimers in the brain [23,24]), the GPCR oligomerization issue
began to gain signiﬁcance, given the potential physiological implica-
tions of this phenomenon. Nevertheless, the straight evidence for a
direct receptor–receptor interaction within the GPCR oligomerization
phenomenon was achieved by means of biophysical techniques based
on resonance energy transfer (RET), like bioluminescence-RET (BRET)
and ﬂuorescence-RET (FRET) (for review see [25]). In addition, the
combination of some ﬂuorescence-based approaches allowed the
identiﬁcation of higher-order GPCR oligomers or receptor mosaics
(RMs) in living cells [26–32]. Finally, these powerful approaches have
been recently used to demonstrate the existence of GPCR oligomers inTransduction mechanismsb Physiological actions in brain
Inhibits AC (↓cAMP) Inhibits synaptic transmission;





Activates AC (↑cAMP) Facilitates transmitter release;
regulation of sensorimotor




Activates AC (↑cAMP) Increases in cAMP in brain slices
Activates Ca2+ channels
Activates PLC (↑IP3/DAG)
Inhibits AC (↓cAMP) Uncouples A1R and mGlu
receptorsActivates PLC (↑IP3/DAG)
enosine receptor [55]. The assay is performed in the presence of the adenosine transport
ol; PLA2, phospholipase A2; PEtOH, phosphatidylethanol; GIRKs, G protein-dependent
Fig. 1. Scheme of the proposed concentration-dependent adenosine receptor hetero-
dimer switch. Upper panel shows the efﬁcacy of adenosine to stimulate A1Rs and A2ARs
within the A1R/A2AR heterodimer. Low concentrations of adenosine activate predom-
inantly A1Rs, which inhibits glutamate release. High concentrations of adenosine also
activate A2ARs, which, by means of the A1R/A2AR intramembrane interaction (blue-red
arrow), antagonizes A1R function, therefore facilitating glutamate release. The
schematic GPCRs diagrams were prepared using PyMOL (PyMOL Molecular Graphics
System, DeLano Scientiﬁc, San Carlos, CA, USA), with the crystal structure of the sensory
rhodopsin II (PDB: 1JGJ) as models. In the lower panel the proposed kinetics of the A1R/
A2AR heterodimer-mediated glutamate release control is shown. Thus, increasing
concentrations of adenosine (0.1–100 μM) produced a biphasic effect, with low and
high concentrations inhibiting and stimulating the evoked release of glutamate in
striatal synaptosomes, respectively.
Adapted from Ref. [47]
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oligomers in mammary glands) [33].
In the last years, a set of publications have demonstrated the
existence of adenosine receptors containing oligomers. For instance, the
A1R has been found to heteromerize with the dopamine D1 receptor
(D1R), this phenomenon being essential for differential desensitization
mechanisms and for receptor trafﬁcking [34]. Similarly, theheterodimer
composed by the A1R and the metabotropic glutamate type 1α
(mGlu1α) receptor seems to play a key role in preventing glutamate
excitotoxicity [35], whereas the physiological role for the proved
heteromerization of theA1R and the purinergic P2Y1 receptor (P2Y1R) is
still under debate [36]. On the other hand, the A2AR also possesses the
ability to oligomerize with the dopamine D2 receptor (D2R) [37,38].
Interestingly, the latter receptor–receptor interaction underlies the
molecular mechanism behind the antagonistic adenosine-dopamine
interactions that regulate the functionof theGABAergic enkephalinergic
neurons [39,40]. Finally, the A2AR also heteromerizes with the
metabotropic glutamate type 5 (mGlu5) receptor [41], and in this
case, a synergistic functional interaction has been demonstrated at both
biochemical and behavioral levels [42–44].
2.1. The adenosine A1 and A2A receptors heterodimer (A1R/A2AR) and the
control of glutamate release in the central nervous system
A1Rs and A2ARs operate through opposing signal transduction
pathways (Table 1). Thus, they have been historically considered as
independent entities in the framework of adenosine physiology.
Interestingly, these adenosine receptors were shown to form homo-
dimers in both ectopic expression systems and in native tissue [24,45].
It was then postulated that the functional receptor placed at the cell
surface of cells was represented by a homodimer [45]. In addition, it
was shown that A1Rs and A2ARs were coexpressed in a variety of cells
like glutamatergic neurons of the hippocampus [46] and the striatum
[47]. Furthermore, heterodimers involving A1Rs and A2ARs were
described in the context of the modulation of the glutamatergic
neurotransmission in the central nervous system [47]. Nevertheless,
the existence of these dimeric forms involving either A1Rs or A2ARs
did not ﬁrst alter the widespread acceptance that these two adenosine
receptors with opposite physiological functions would signal inde-
pendently. However, some evidence strongly indicated a potential
interaction between A1Rs and A2ARs [48–50][48], suggesting the
possibility that these receptors could establish a molecular and/or
functional cross-talk, i.e. as if they were part of the same molecular
transduction complex or signalosome, thus affording a logical and
economical device to ﬁne-tune adenosine neuromodulation.
Initially, as described for the neuropeptide and monoamine
receptor–receptor interaction studies (see above), the functional
cross-talk between the A1R and the A2AR was assessed by means of
radioligand-binding experiments. Thus, these approaches revealed
that the formation of the A1R/A2AR heteromer per se did not modify
the afﬁnity of A1Rs or A2ARs for their respective agonists. But
interestingly, when the A1R/A2AR heteromer was challenged with an
A2AR agonist, the afﬁnity of the A1R for its agonist decreased
signiﬁcantly. Conversely, the activation of the A1R/A2AR heteromer
with an A1R agonist did not alter the A2AR binding characteristics.
Therefore, it could be concluded that, within the A1R/A2AR heteromer,
the agonist-mediated A1R responsiveness is modulated by the A2AR,
whereas the binding properties of the latter were not altered by the
A1R challenge. This ability of the A2AR to control the A1R within the
A1R/A2AR heteromer has been further conﬁrmed by functional
experiments (i.e. determination of receptor-mediated second mes-
senger generation). For instance, upon the formation of the A1R/A2AR
heteromer, the A2AR challenge signiﬁcantly decreased the A1R-
mediated intracellular calcium mobilization [47]. Overall, these
results suggest that under certain circumstances the A2AR can control
the A1R functionality, whereas the reverse does not happen.The question that is still remaining focuses on whether the
formation of the A1R/A2AR heteromer might play a physiological role
in native brain preparations. This issue is of major relevance, since the
involvement of GPCR oligomerization in pathophysiological condi-
tions remains unexplored. Interestingly, there is strong evidence
pointing to the existence of the A1R/A2AR heteromer in the brain areas
where the distribution of A1Rs and A2ARs clearly overlaps, for instance
in the dopamine-rich regions [51,52]. Indeed, ultrastructural analysis
by immunolelectron microscopy experiments in the rat striatum have
revealed that these receptors codistribute and colocalize in striatal
glutamatergic synapses [47] (Fig. 2). In addition, co-immunoprecip-
itation studies have clearly shown that the A1R and A2AR are co-
puriﬁed from rat striatal synaptosomes when speciﬁc antibodies are
used, thus suggesting the existence of A1R/A2AR heteromers in the
striatal glutamatergic synapses and/or perisynaptic regions [47].
In the excitatory glutamatergic synapses themost accepted role for
adenosine is the inhibition of synaptic transmission (i.e. inhibition of
glutamate release) through the activation of presynaptic A1Rs. In fact,
the A1R constitutes the prototypical inhibitory Gi/o protein-coupled
receptor whose stimulation decreases the probability of neurotrans-
mitter release [53]. On the other hand, the use of particular
stimulating conditions together with pharmacological tools with
adequate selectivity to hamper A2AR functioning, has made possible
the identiﬁcation of a parallel capacity of adenosine to facilitate the
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(Fig. 2). Therefore, one can easily ask the following question: how
does adenosine decide between A1Rs and A2ARs in the glutamatergic
nerve terminal in order to control glutamate release? To answer this
question several facts need to be primarily established. First, that the
A1R and the A2AR have different afﬁnities for adenosine with the
former showing a higher afﬁnity for this nucleoside than the latter
(Table 1) [55]. Therefore, at low concentrations of adenosine the A1R
will be primarily stimulated and glutamate release inhibited (Fig. 1).
In contrast, at high concentrations of adenosine both A1Rs and A2ARs
could potentially be activated, and thus the question arises how the
control of glutamate release will be established under these
circumstances. How can the integration of A1Rs and A2ARs signals
take place? The evidence described so far point to the fact that the
A1R/A2AR heteromer located at the glutamatergic terminal makes
possible this integration, since the A1R responsiveness within the
heteromer is under the control of the A2AR. Therefore, at high
concentrations of adenosine the A2AR stimulation will abrogate the
A1R functioning by means of a phenomenon of allosteric cross-
inhibition, which will lead to predominant facilitation of glutamate
release (Fig. 1). Then, it can be concluded that A1R/A2AR heteromer-
ization provides a molecular framework that allows adenosine to
exert a ﬁne-tune modulation of glutamate release in the striatum asFig. 2. Schematic representation of the striatal spine module (SSM) within the striatal spiny
striatum. As described for the A2AR the immunoreactivity was very strong in the caudate pu
light microscopic level. Ctx, cortex; LS, lateral septum; LV, lateral ventricle. Adapted from
GABAergic neuron of the caudate putamen. Adapted from Ref. [130]. (c) Electron micrograp
reaction product (immunoreactivity for A1Rs) ﬁlled axon terminals -B- establishing asymme
were localized along the extrasynaptic plasma membrane (arrows). Adapted from Ref. [47]
micrograph showing immunoreactivity for A2AR, D2R and mGlu5 receptor in rat stri
Immunoparticles for A2AR (10 nm size, arrows), D2R (15 nm size, crossed arrows) and m
perisynaptic plasmamembrane of the same dendritic spine (s) establishing excitatory synapt
the SSM. The MSN is the most common neuron in the striatum and it receives two main inp
afferents from the mesencephalon. The A1R/A2AR heterodimer is located in the glutamatergic
located in the dendritic spine of the enkephalin medium spiny neuron and controls the exci
(e.g. A1R/A2AR and A2AR/D2R/mGlu5 receptor) determines the predominant signalling pathw
based adenosine cycle [131]. Glial cells can release ATP via direct release through hemichann
synaptic cleft. The ATP at the extracellular level is quickly degraded into adenosine (Ado
transporters (nt). At the intracellular level adenosine concentration is mainly controlled by
ﬁnally ATP [131].the A1R/A2AR heteromer is found in the glutamatergic terminals of the
striatal spine module (SSM) (see below and Fig. 2). Thus, the
extracellular adenosine switches from inhibition to facilitation thanks
to the A1R/A2AR heteromer [47]. It is important to keep in mind that
this scenario might be true in brain and related to the control of
neurotransmitter release, where a proper A1R and A2AR co-localiza-
tion and stoichiometry allow the existence of a balanced A1R/A2AR
oligomer. However, in the situation where either an unbalanced A1R/
A2AR oligomer exist (i.e. existence of spare A2AR that sensitize the
A2AR-mediated adenosine response) or that the A1R and the A2AR do
not oligomerize (i.e. do not co-distribute), then the predominance of a
distinctive adenosine receptor-mediated function (A1R or A2AR) will
be observed, as it has been recently described [56]. Thus, more work is
needed to fully characterize the functionality of the A1R/A2AR
oligomer outside the SSM and also the mechanism by which the
oligomer couples to G protein(s) (i.e. do the A1R/A2AR oligomer
couples to a single G protein or simultaneously to Gi and GS?). Overall,
the A1R/A2AR heteromer confers a rationale for the existence of
heteromers of isoreceptors (receptors for the same neurotransmitter)
and demonstrates that neurotransmitter heteromers composed of
isoreceptors with different afﬁnities for their endogenous neuro-
transmitter can act as concentration-dependent processors that exert
a ﬁne-tune modulation of neurotransmission (Fig. 1).neuron (MSN). (a) Immunoreactivity of NECAB2, an A2AR interacting protein, in the rat
tamen (Cpu) [130] as revealed by a pre-embedding immunoperoxidase method at the
Ref. [130]. (b) High magniﬁcation picture showing immunoreactivity for NECAB2 in a
h showing the presynaptic co-localization of A1Rs and A2ARs in rat striatum. Peroxidase
trical synapses with spines -S-, in which immunoparticles (immunoreactivity for A2ARs)
. (d) Subcellular distribution of A2AR, D2R and mGlu5 receptor in rat striatum. Electron
atum as revealed using a triple-labeling post-embedding immunogold technique.
Glu5 receptor (20 nm size, arrowheads) were detected along the extrasynaptic and
ic contact with axon terminals. Adapted from Ref. [129]. (e) Schematic representation of
uts: glutamatergic afferents from cortical, limbic and thalamic areas, and dopaminergic
terminal and controls the glutamate release. The A2AR/D2R/mGlu5 receptor oligomer is
tability of the MSN. The differential stimulation of the units of the receptor heteromers
ay (see [42,43]). The extracellular adenosine levels are thought to be regulated by a glial-
els (h-ch) and/or by vesicular release. Also, ATP can be co-released with glutamate at the
) by ectonucleotidases. Ado can also be released directly via equilibrative nucleoside
adenosine kinase, which is part of a substrate cycle between adenosine and AMP and
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3.1. A1R and dopamine D1 receptor (D1R) oligomers
Dopamine plays a key role in a large variety of functions in the CNS
including short-term memory and motor, attention and reward
control [57–59]. Imbalance in dopaminergic neurotransmission has
been associated with drug addiction [60] and CNS alterations in stress
conditions [61]. Furthermore, dysfunction of dopaminergic neuro-
transmission has been also involved in psychiatric and neurological
disorders including Parkinson's disease, schizophrenia and bipolar
disorders [62,63]. Dopamine speciﬁcally acts on GPCRs located in the
plasma membrane of cells and, based on morphological and
pharmacological characteristics, these receptors are classiﬁed as D1-
like, which include the D1R and the D5R, and D2-like receptors, which
include the long and short isoforms of the D2R (termed D2LR and D2SR,
respectively), the D3R and the D4R [63].
The modulatory effects of adenosine on dopamine systems have
been investigated in view of their relevance to human pathology such
as schizophrenia and Parkinson's disease. Antagonistic adenosine/
dopamine interactions have been widely reported, showing that
adenosine can inhibit several effects of dopamine in the cerebral
cortex and basal ganglia. In rat models of Parkinson's disease, for
instance, it was shown that nonselective adenosine receptor antago-
nists (i.e. either caffeine or theophyllamine) enhanced the effect of
L-DOPA and other dopamine receptor agonists increasing motor
activity [64]. Similarly, it was also described in unilaterally 6-OH-
dopamine (which speciﬁcally destroys the nigrostriatal dopamine
pathway) lesioned rats that the A1R selective antagonist CPT
enhanced the motor activating effects of the D1R selective agonist
SKF 38393 [65], while the A1R selective agonist CPA counteracted SKF
38393-induced grooming behavior [66]. Hence, in order to explain the
results obtained in a large number of behavioral studies, it was
suggested that antagonistic adenosine/dopamine interactions were, at
least in part, caused by an intramembrane interaction between
speciﬁc subtypes of dopamine and adenosine receptors, in this case
A1Rs and D1Rs [67,68].
The ﬁrst evidence of a receptor–receptor interaction involving the
A1R and the D1R was provided by means of co-immunoprecipitation
experiments and confocal microscopy analysis in co-transfected
ﬁbroblast Ltk-cells and cortical neurons in culture [69]. Interestingly,
this selective A1R/D1R heteromerization disappeared after pretreat-
ment with a selective D1R agonist, but not after combined pretreat-
ment with D1R and A1R agonists. Likewise, the D1R uncoupling from
adenylyl cyclase only occurred when the A1R/D1R heteromer was co-
activated, while the A1R agonist alone did not substantially reduce the
D1R agonist-induced accumulation of cAMP [69]. Similarly, by means
of double immunoﬂuorescence experiments with confocal microsco-
py, a high degree of A1R and D1R co-localization was found in both co-
transfected ﬁbroblast cells and cortical neurons in culture [70]. In this
study A1R/D1R coimmunoprecipitation was also demonstrated in
native tissue, for instance in samples from rat nucleus accumbens.
Interestingly, in the native tissue A1R/D1R coimmunoprecipitation
was reduced only when rats were treated with cocaine, while co-
activation of A1Rs prevented receptor uncoupling [70].
The above-commented results may then explain the well-
documented antagonistic A1R/D1R receptor–receptor interactions
found in the neuronal networks of the brain, since they indicate
that A1R/D1R heteromerization could determine changes in the
pharmacological proﬁle of the receptors, for instance, activation of
the A1R could modulate D1R signaling. One of the mechanisms that
may explain this action is based on the ability of A1R activation within
the heteromer to change the binding characteristics of dopamine to
the D1R. Accordingly, it was ﬁrstly described in crude membrane
preparations from cell lines and rat striatum that activation of A1Rs
reduced the proportion of D1Rs in the high-afﬁnity state withoutchanging the dissociation constants of the high- and the low afﬁnity
binding sites [68,71,72]. Thus, the high afﬁnity form of the receptor
would be partially or completely lost in the presence of agonists
activating A1Rs, while in the absence of cross-modulation the binding
of dopamine to the D1R would involve both the low afﬁnity (80-90%)
and the high afﬁnity form of the receptor [72]. Similarly, it was
reported that the adenosine A1R selective antagonist DPCPX had an
effect on the Ki value of the D1R selective agonist SKF 38393 in A1R/
D1R transfected cells, thus adenosine would exert a tonic inhibition of
dopamine in the D1Rmediated function through the A1R/D1R complex
[73]. In addition, radioligand binding experiments performed in
cotransfected A1R/D1R cells showed that the adenosine A1R-mediated
modulation of D1R induced a concentration-dependent decrease in
the afﬁnity of the D1R agonist SKF38393 [74]. Overall, it is now well
accepted that the simultaneous activation of the A1R/D1R heteromer
may allow the antagonistic intramembrane receptor–receptor inter-
action to take place, and it has been suggested that one functional
meaning of this interaction is the uncoupling of the D1R from Gs
protein with the disappearance of the D1R high afﬁnity state [75].
On the other hand, the uncoupling from the downstream signaling
effectors may also be dependent of A1R/D1R heteromerization, which
in fact appears to control the temporal dynamics of receptor
activation and down-regulation [69]. As described earlier, upon co-
activation of A1Rs and D1Rs in co-transfected ﬁbroblast cells and in
cortical neurons in culture the heteromer complex was maintained,
while during individual treatments heteromerization disappeared,
thus indicating that co-activation induced heteromer stabilization.
Similarly, pretreatment with an A1R agonist caused co-clustering (co-
aggregation) of A1Rs and D1Rs, which was blocked by combined
pretreatment with A1R and D1R agonists [69]. These results indicated
that the movement of the heteromer and/or clusters of heteromers in
the plasma membrane could be agonist-dependent, and that receptor
trafﬁcking may depend on the activity of the two receptors of the
heteromer. As a result, it has been suggested that D1R desensitization
may be mainly caused by a prolonged allosteric change in the D1R
brought about by the A1R/D1R heteromeric complex; speciﬁcally
these changes could consist of phosphorylation events and/or
association with beta-arrestin-like molecules that ﬁnally would lead
to a reduced Gs coupling of the D1R [76,77].
Consequently, the A1R/D1R receptor–receptor interaction in this
heteromer is relevant not only for acute A1R antagonism of D1R
signaling but also for a persistent long-term antagonism of A1R to D1R
signaling to the Gs protein. Therefore, it has been postulated that
novel therapeutic approaches, for instance in Parkinson's disease, may
be developed taking into account not only the particular character-
istics of the receptors within the heteromer, but also the fact that the
pathology may induce changes in such receptor–receptor interactions
involved in the function of neuronal networks of the brain, such as in
the basal ganglia and prefrontal cortex [78].
3.2. A1R and metabotropic glutamate type 1 (mGlu1) receptor oligomers
Glutamate is the main excitatory neurotransmitter in the mam-
malian central nervous system and exerts its effects through speciﬁc
cell surface receptors, namely ionotropic glutamate (iGlu) receptors –
that form ion channels – and metabotropic glutamate (mGlu)
receptors, which are coupled to G proteins [79,80]. To date, eight
members of the metabotropic glutamate receptor family have been
identiﬁed and categorized into three groups (I, II and III), based on
their sequence homology, agonist selectivity, and signal transduction
pathways [79]. Group I contains the mGlu1 and mGlu5 receptor
subtypes, which are coupled to phospholipase C in transfected cells
and have quisqualic acid as their most potent agonist. Five splice
variants of the mGlu1 receptor have been described [79,81].
Interestingly, these splice variants differ between them in the length
of their C-terminal tail, which might play a role in the subcellular
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metabotropic glutamate type 1α (mGlu1α) receptor interacts with
tubulin, and it has been proposed that the latter can regulate the cell
surface expression of the receptor and its plasma membrane
anchoring [83,84]. Noteworthy, another cytoskeletal protein, 4.1 G,
has also been described as a binding partner of the mGlu1α receptor
[85]. This multifunctional protein, which is a critical component of the
spectrin/actin cytoskeleton, plays an important structural and
regulatory role in the stabilization and assembly of receptors into
themembranes. Interestingly, the 4.1 G protein has also been found to
bind to the third intracellular loop of the A1R and to play a regulatory
role in the trafﬁcking and down-regulation of this receptor [85].
As described earlier, among the numerous neurophysiological
actions of adenosine, the inhibition of glutamate neurotransmission
has been studied in several brain regions [7,86]. The activation of
presynaptic adenosine A1Rs, which leads to a direct inhibitory effect of
G protein βγ-subunits on voltage-dependent Ca2+ channels, has been
described as one of the mechanisms involved in the decrease of the
probability of glutamate release to the synaptic space [53,87–89].
Interestingly, the A1R-mediated ﬁne-tuning modulation of glutama-
tergic neurotransmission has been demonstrated to occur, at least in
part, by means of an interaction between the A1R and the mGlu1α
receptor [35]. Thus, while A1R/mGlu1α receptor–receptor coupling
could occur through speciﬁc targeting proteins, such as protein 4.1 G,
a direct receptor–receptor interaction between the A1R and the
mGlu1α receptor would also be possible. In fact, the C-terminal tail of
themGlu1α receptor has been shown to be necessary to reach the A1R/
mGlu1α receptor heteromer formation, since other splice variants, as
themGlu1β receptor with a shorter C-terminal tail or a deletedmutant
of the mGlu1α receptor lacking the C-terminal cytoplasmatic domain
did not interact with the adenosine A1R [35]. In these experiments
biochemical and functional evidence was also provided for a A1R/
mGlu1α receptor receptor–receptor interaction. Co-immunoprecipi-
tation experiments showed a close and subtype-speciﬁc interaction
between A1Rs and mGlu1α receptors in both rat cerebellar synapto-
somes and co-transfected HEK-293 cells. Also, in primary cultures of
cortical neurons a high degree of co-localization was also observed
[35]. In these rat cortical neurons, it was suggested by means of
NMDA-mediated excitotoxicity experiments that the timing in A1R
and mGlu1α receptor activation is very important to achieve a
maximum effect in adenosine- and glutamate-mediated neuroprotec-
tion/neurodegeneration. Similarly, A1Rs and mGlu1α receptors may
form part of a signalling complex in vivo that could play a critical role
in ﬁne-tuning neurotransmission at glutamatergic synapses. This was
substantiated by using transiently co-transfected HEK-293 cells, in
which a synergy between both receptors in receptor-evoked [Ca2+]i
signaling was shown, as previously reported [90]. Overall, these
results demonstrate that a functional cross-talk occurs between A1Rs
and mGlu1α receptors. These results open new perspectives for the
development of novel agents to treat neuropsychiatric disorders in
which abnormal glutamatergic neurotransmission is involved.
4. Adenosine A2 receptor (A2R) containing oligomers
4.1. A2AR and dopamine D2 receptor (D2R) oligomers
In the striatum, more than the 95% of the neuronal population is
comprised by themedium spiny GABAergic efferent neurons. There are
two subtypes of these GABAergic striatal neurons, the GABAergic
striatopallidal neurons, which can be called enkephalinergic neurons,
since they express the peptide enkephalin, and the GABAergic
striatonigral-striatoentopeduncular neurons, called also as GABAergic
dynorphynergic neurons, since they express the peptide dynorphin
(and also substance P). Interestingly, while the GABAergic enkephali-
nergic neuron predominantly expresses A2ARs and D2Rs, the GABAergic
dynorphynergic neuron expresses A1Rs and D1Rs [18,67,91]. Currently,it is well accepted that the A2AR plays a modulatory role in the CNS in
general and in the striatum in particular, and that this A2AR-mediated
neuromodulatory role is somehow related to the ability of this receptor
to heteromerize with other GPCRs. Indeed, in the last decade the
existence of a direct receptor–receptor interaction between A2ARs and
D2Rs has been demonstrated [38,92]. Thus, it has been postulated that
while the previously describedA1R/D1R interactionwouldmodulate the
function of the GABAergic dynorphynergic neurons, the A2AR/D2R
interaction would modulate the function of the GABAergic enkephali-
nergic neurons [67,68].
The A2AR/D2R receptor–receptor interaction takes place in both
the somatodendritic area and in the nerve terminals of the GABAergic
enkephalinergic neurons [40,42,43,68]. At this level, the coexistence
of two reciprocal antagonistic interactions between these receptors
has been studied. First, it has been demonstrated that the stimulation
of D2Rs in the globus pallidus produces a strong counteraction of
A2AR-mediated GABA release [93]. Similarly, recent studies in animal
models of Parkinson's disease have suggested that the pallidal A2AR/
D2R interaction may contribute to the antiparkinsonian effects of the
co-administration of A2AR selective antagonists and L-DOPA or D2R
selective agonists. On the other hand, it has been shown that there
exists a strong tonic activation of D2R blocking the ability of the A2AR
to signal through the cAMP-PKA pathway. In this way, in vivo
administration of a D2R selective antagonist in the rodent striatum
produces a signiﬁcant increase in the expression of c-fos and
preproenkephalin genes, which depends on the ability of the D2R to
tonically block A2AR signaling activated by endogenous adenosine
[94]. Overall, two reciprocal antagonistic A2AR/D2R interactions have
been described, namely an intermembrane interaction in which the
A2AR mediates the inhibition of the D2R, thus modulating neuronal
excitability and neurotransmitter release, and an interaction at the
level of adenylyl-cyclase in which the D2R inhibits A2AR-mediated
protein phosphorylation and gene expression.
There are two possible mechanisms to explain the apparently
incompatible coexistence of two reciprocal antagonistic A2AR/D2R
interactions. Firstly, it has been suggested that there exists a different
G-protein coupling depending on the conformation of the D2R.
Accordingly, it has been proposed that the D2R couples to Gi/o, and
therefore negatively to adenylyl-cyclase, when not being part of the
A2AR/D2R heteromer, while it switches to Gq/11-PLC signaling when
heteromerization occurs. And secondly, the presence of a third
partner has been proposed, namely the mGlu5 receptor, which
could interact with the A2AR (see below). Interestingly, it has been
shown both in transfected cells and in the striatum that upon co-
stimulation of A2ARs and mGlu5 receptors a synergistic effect is
produced on c-fos expression related to changes at the adenyl-cyclase
and the MAPK levels [41,95]. In addition, in vivo experiments have
demonstrated that co-stimulation A2ARs and mGlu5Rs in the presence
of a selective D2R agonist permits the A2AR to be liberated from the
tonic inhibitory effect of the D2R on A2A signals through the cAMP-
PKA pathway [96].
In the last years, we and others have demonstrated the existence of
the A2AR/D2R heteromer in living cells by biochemical (i.e. co-
immunoprecipitation) and by biophysical (i.e. FRET and BRET)
approaches [38,40,97–99]. In addition, by computerized modeling,
and pull-down and mass spectrometry techniques, we have also
demonstrated that the heteromerization between the A2AR and the
D2R depends on a coulombic interaction between the third intracellular
loop (3IL) of the D2R and the C-terminal tail of the A2AR receptor
[38,92,100,101]. Therefore, a positively charged arginine rich motif
located in the N-terminal part of the D2R-3IL may interact with two
different negatively chargedmotifs from the C-terminal tail of the A2AR,
namely the 388HELKGVCPEPPGLDDPLAQDGAVGS412 domain which
contains two adjacent aspartic residues or the 370SAQEpSQGNT378
domain which contains a phosphorylable serine residue (S374), and
thus forming electrostatic bonds of covalent-like strength [100,101].
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the serine 374 to alanine (S374A) reduces A2AR/D2R heteromerization
and blocks the A2AR allosteric modulation of the dopamine D2R [102], a
result thathas been further conﬁrmed [103]. Also,when theS374Apoint
substitution was accompanied with the mutation of the two negatively
charged aspartates in the A2AR C-terminal tail (D401A/D402A, see
above) a synergistic reduction in the physical A2AR/D2R interaction was
observed and in the loss of antagonistic allosteric modulation over the
A2AR/D2R interface [104]. Thus, these results further corroborate the
existence of an electrostatic interaction between the C-terminal tail of
the A2AR and the 3IL of the D2R. In addition, by using synthetic
transmembrane (TM) α-helix peptides of the D2R we have recently
explored the role of TM helix interactions within the A2AR/D2R
heteromer interface [104]. Thus, we have evidence that the TMdomains
IV and V of the D2R play a critical role in the A2AR/D2R heteromer
interface since the incubation with peptides corresponding to these
domains signiﬁcantly reduced the ability of the A2AR and the D2R to
heteromerize. Also, the incubation with TM-IV or TM-V blocked the
allosteric modulation normally found in the A2AR/D2R heteromer [104].
Overall, the A2AR double aspartate mutation (D401A/D402A) together
with the serinemutation (S374A) had deleterious consequences for the
allosteric communicationwithin theA2AR/D2Rheteromer, thus pointing
toward the relevance of these residues in the formation of an
electrostatic zip between the A2AR and the D2R, which is regulated by
phosphorylation events, and thus necessary for the direct physical
receptor–receptor cross-talk.
4.2. A2AR and metabotropic glutamate type 5 (mGlu5) receptor oligomers
In some behavioral animal models the treatment with mGlu5
receptor agonists and antagonists produce similar effects to that
described for the treatment with A2AR agonists and antagonists,
respectively, namely the selective modulation of D2R-mediated
effects. Brieﬂy, while a selective mGlu5 receptor agonist mainly
inhibits the D2R agonists-mediated motor activation [105], a mGlu5
receptor antagonist counteract the effects of D2R antagonists [106].
Thus, A2AR and mGlu5 receptor agonists and A2AR and mGlu5 receptor
antagonists showed synergistic effects at the behavioral level
[105,107,108]. In addition, in the striopallidal complex the mGlu5
receptor showed a very similar localization to that described for the
A2AR [52,109]. Also, the mGlu5 receptor immunoreactivity was
commonly found perisynaptically to asymmetric postsynaptic synap-
ses [109,110]. Overall, these studies provided behavioral and
morphological basis for the possible existence of functional interac-
tions between striatal A2ARs and mGlu5 receptors.
Interestingly, it has been possible to demonstrate the existence of
heteromeric receptor complexes between A2ARs and mGlu5 receptors
in both living cells (i.e. HEK-293 cells) and in native tissue
preparations (i.e. rat striatal membranes) [41]. Thus, it was initially
found that A2ARs and mGlu5 receptors were co-distributed at the
membrane surface of co-transfected HEK-293 cells and also that they
were co-immunoprecipitated from cell extracts when speciﬁc anti-
bodies were used [41]. Also, a strong A2AR and mGlu5 receptor co-
distribution in rat striatal primary cultures was shown [40]. On the
other hand, a number of studies have focused on the functionality of
the A2AR/mGlu5 receptor heteromeric complex, and it has been
suggested that the former oligomer may play a major role on striatal
neuronal function and dysfunction. Accordingly, functional A2AR/
mGlu5 receptor synergistic interactions have been demonstrated both
in co-transfected cells and in the rat striatum. Thus, in HEK-293 cells it
was shown that upon A2AR/mGlu5 receptor co-activation a synergistic
interaction occurred at the level of extracellular signal-regulated
kinase 1/2 phosphorylation (ERK) and of c-fos expression [41].
Interestingly, this synergism was shown to occur at the level of the
mitogen-activated protein kinase (MAPK) cascade [111,112]; alter-
natively, it could also happen that upon co-activation of the oligomer,this receptor complex would assemble with receptor tyrosine kinases
or non-receptor tyrosine kinase Src, leading to ERK activation [113–
117]. Altogether, it has been then suggested that the A2AR/mGlu5
receptor heteromeric complex may be involved in striatal neuron
plasticity (e.g. long-term potentiation and long-term depression)
[111,112]. In this way, it has been suggested the possibility of a
synergic interaction within the A2AR/mGlu5 receptor oligomeric
complex modulating mGlu5 receptor desensitization, which has
been demonstrated for NMDA/mGlu5 receptor and group II mGlu/
mGlu5 receptor interactions [118,119]. However, this interaction
would be dependent on a synergistic interaction at the second-
messenger level (Ca2+ mobilization) [118,119], a situation that has
not been possible to demonstrate in A2AR/mGlu5 receptor cotrans-
fected HEK-293 cells [41].
Similar to the data obtained in cultured cells, studies in striatal
slices have shown that stimulation of the mGlu5 receptor potentiates
A2AR signalling in a MAPK-dependent manner [95]. Interestingly,
MAPK activation is involved in the recruitment of ionotropic
glutamate AMPA receptors to the postsynaptic density [120,121],
thus the A2AR/mGlu5 receptor heteromer would be able to modulate
plastic changes in the striatal spine module (SSM, see below). In fact,
it has been demonstrated that the pharmacological or genetic
inactivation of A2ARs or mGlu5 receptors impairs corticostriatal
long-term potentiation [122,123]. The A2AR/mGlu5 receptor syner-
gism has also been demonstrated in the rat striatum, mediating c-fos
expression and thus counteracting phencyclidine induced motor
activity [41]. Interestingly, it is well known that this motor activity is
dependent on dopamine D2R activity, thus it has been suggested, as
commented above, that upon A2AR/mGlu5 receptor co-stimulation it
is blocked D2R mediated transmission at the behavioral level.
Similarly, chronic but not acute treatment with a mGlu5 receptor
antagonist reversed the akinetic deﬁcit in a model of Parkinson's
disease [124]. In this case, it would seem that the potentiation of D2R
activity could in part be caused by the internalisation and down-
regulation of the A2AR/mGlu5 receptor heteromeric receptor complex,
thus removing the D2R from inhibition of its signalling. In addition, it
has also been shown that an acute effect of mGlu5 receptors on
dopamine D2R activity exists, since a mGlu5 receptor antagonist
induced counteraction of the blockade with haloperidol of the D2R,
thus observing in rats reduced rigidity and catalepsy [106], effects that
may in part be exerted at the network level (e.g. at the level of the
subthalamic–nigral glutamate system).
Overall, A2AR/mGlu5 receptor and also D2R/A2AR/mGlu5 receptor
(see below) interactions provide the rationale for the application of
A2AR antagonists and the possible application of mGlu5 receptor
antagonists in Parkinson's disease [67,106,107,125,126].
5. The striatal spine module as a paradigm of ARs integrative
functioning in the brain
The striatum receives the densest dopamine innervation and
contains the highest concentration of dopamine receptors in the brain
[127,128]. As a consequence, dopamine plays a key role in motor
activity and goal-directed behaviors and also in the pathophysiology
of diverse disorders, including Parkinson's disease and drug addiction
[39]. Moreover, in this brain area, apart of the pivotal role played by
dopamine, there are other neurotransmitters/neuromodulators that
participate in the proper striatal functioning, for instance glutamate,
acetylcholine, GABA, adenosine, etc., Therefore, interactions among
striatal neurotransmitters/neuromodulators determines the types of
plasticity taking place at the glutamatergic synapses onto striatal
neurons, and thus complex interactions between the receptors for
these neurotransmitters/neuromodulators are currently established.
Interestingly, we have demonstrated the existence of oligomeric
complexes that simultaneously contain adenosine, dopamine and
glutamate receptors (e.g., A2AR/D2R/mGlu5 receptor) and that these
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Indeed, the recent ﬂuorescence-based approaches on the study of
protein-protein interactions [25] have allowed us to demonstrate the
existence of higher-order A2AR/D2R/mGlu5 receptor oligomers or
RMs. Initially, by using bimolecular ﬂuorescence complementation
(BiFC), we visualized for the ﬁrst time the occurrence of D2R/mGlu5
receptor heterodimers in living cells [129]. Furthermore, the combi-
nation of BiFC and BRET techniques allowed us to detect the existence
of receptor oligomers containing more than two protomers, namely
A2AR/D2R/mGlu5 receptor higher-order oligomers or RMs [129]. Next,
by using triple-labeling post-embedding immunogold and detection
at electron microscopic level the precise simultaneous distribution of
A2AR, D2R and mGlu5 receptor in striatal neurons have been
performed. It is important to mention here that these three receptors
co-distributed in post-synaptic structures along the extra-synaptic
and peri-synaptic plasma membrane of spines, establishing asym-
metrical, putative glutamatergic, synapses with axon terminals [129]
(Fig. 2, inset panel). Overall, the A2AR/D2R/mGlu5 receptor oligomeric
complex is located adjacent to the glutamatergic synapse of the
dendritic spine of the enkephalin MSN, and their cross-talk within the
receptor heteromers might help in theory to modulate postsynaptic
plastic changes at the glutamatergic synapse [42,43] (Fig. 2).
The A2AR and group I glutamate metabotropic (mGlu) receptor
agonists could synergistically reduce afﬁnity of striatal D2R. Therefore,
in membrane preparations from rat striatum, the stimulation of either
the A2AR or the mGlu5 receptor produces a decrease in the afﬁnity of
the D2R for agonists and a decrease in D2R agonist-mediated motor
activation [105,125]. In addition, co-stimulation of A2AR and mGlu5
receptor produces a synergistic antagonistic modulation of D2R ligand
binding and function that is signiﬁcantly stronger than the reduction
induced by stimulation of either receptor alone [105]. Thus, co-
administration of A2AR and mGlu5 receptor agonists inhibits motor
activation induced by D2R agonists [41,105]. Therefore, it is postulated
that the formation of A2AR/D2R/mGlu5 receptor oligomer is a key step
for the correct shape of the SSM as a functional local module in the
striatum (Fig. 2). Interestingly, the SSM, which is constituted by the
dendritic spine of the MSN, its glutamatergic and dopaminergic
terminals and astroglial processes, could be considered the minimum
portion that operates as an integrative independent unit in the
striatum and it provides an example of the extraordinary degree of
computation that takes place in local modules (Fig. 2) [42,43]. Indeed,
the formation of glutamate, dopamine and adenosine receptors
oligomers in the striatum are behind the SSM performance as a
local module, thus the coordinate operation of these oligomers within
the SSM is associated with particular elaborated functions in the local
module. In the SSM, the A2AR/D2R/mGlu5 receptor oligomeric
complex is located extrasynaptically and adjacent to the glutamater-
gic synapse of the dendritic spine of enkephalin MSNs, where they are
activated by volume transmission and their cross-talk within the
complex helps to modulate postsynaptic plastic changes at the
glutamatergic synapse. On the other hand, the A1R/A2AR heteromeric
complex is found in glutamatergic terminals and the molecular cross-
talk between the two receptors in the heteromer helps to modulate
glutamate release (Fig. 2). Overall, the formation of oligomeric
complexes in the SSM containing adenosine receptors allows a
much more elaborated tuning in the regulation of both presynaptic
and postsynaptic neuronal responses in the striatal local circuitry.
6. Concluding remarks
The existence of GPCR oligomers is now broadly accepted and the
functional meaning of receptor oligomerization is becoming revealed
(http://data.gpcr-okb.org/gpcr-okb/). In the CNS the oligomerization
of neurotransmitter/neuromodulator receptors confers functional
entities which possess different biochemical characteristics with
respect to the individual components of the heteromer. Thus, thesignalling mediated by single stimulation of any receptor within the
oligomer may be, from a qualitative and/or quantitative point of view,
different from the one obtained upon the multiple stimulation of the
oligomer, as a consequence in the CNS the oligomer may function as a
computational device that modulates information ﬂow between
neurons. In this way, the adenosine receptors in general and the
oligomers containing these receptors in particular constitute a clear
example of integration of different modes of communication (i.e.
wiring transmission vs volume transmission) mediated by neuro-
transmitters and neuromodulators (i.e. dopamine, glutamate, acet-
hylcholine and adenosine). Consequently, the challenge now would
be to fully characterize these adenosine containing oligomers in
native tissue in order to determine how these oligomers impinge into
neuronal functioning in both normal and pathological conditions.
Regarding this last issue, several concepts should be taken into
account to fully understand the role of these oligomers: the
differential spatio-temporal expression pattern of each independent
receptorwithin the oligomer, the stoichiometry and relative afﬁnity of
these receptors within the RMs, and the functional and molecular
cross-talk between the different receptors of a named oligomer.
Overall, the knowledge of these issues will be necessary before the
design of any adenosine receptor oligomer-based therapeutic
strategy.
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